nach oben

Journal of Hepato-Biliary-Pancreatic Sciences

Erschienen in:

01.07.2012 | Review article

Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options

verfasst von: Junichi Shoda, Kazunori Ishige, Hiroaki Sugiyama, Toru Kawamoto

Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Biliary tract carcinoma (BTC) is a lethal malignancy. This lethality is essentially attributed to both slow carcinogenesis occurring under complex pathological circumstances and to the asymptomatic growth of BTC infiltrating the surrounding structures by varying routes. The disease is therefore usually detected at an advanced stage with a high frequency of distant organ metastasis. To date, conventional chemotherapy and radiation therapy have been notably ineffective against BTC. For an improved treatment outcome of BTC and prolonged survival, there is now a real and urgent need to focus on developing novel and potent therapeutic strategies aimed at exploiting select molecular targets associated with tumor proliferation, invasion, and/or metastasis that would impact in a significant way on clinical outcome. The outcomes of recent studies, by the analysis of BTC cells, BTC animal models, and clinical specimens of BTC patients, have revealed, in detail, the molecular mechanism of carcinogenesis and tumor progression of BTC, and these studies have exploited select molecular targets that could significantly impact the clinical outcome. In the near future, the development of new molecular targeting drugs with potent efficacy against BTC, and the performance of randomized clinical trials of these drugs are urgent and essential for the treatment of patients with BTC.

Japan VSo. Tokyo (Japan): Japanese Ministry of Health and Welfare: Statistics Assoc.; 1998.

Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7.PubMedCrossRef

Taylar-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48:816–20.CrossRef

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.PubMedCrossRef

Randi G, Franceschi S, Vecchia CL. Gallbladder cancer world wide: geographical distribution and risk factors. Int J Cancer. 2006;118:1591–602.PubMedCrossRef

Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2008;51:349–64.CrossRef

Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol. 2002;17:1049–55.PubMedCrossRef

Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–25.PubMedCrossRef

Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41:5–15.PubMedCrossRef

10.

Zen Y, Fujii T, Itatsu K, et al. Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. Mod Pathol. 2006;19:1243–54.PubMedCrossRef

11.

Zen Y, Fujii T, Itatsu K, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology. 2006;44:1333–43.PubMedCrossRef

12.

Sirica AE. Bile duct cancer, ERBB-2, and COX-2. Sci Med. 2002;8:268–77.

13.

Endo K, Yoon B, Pairojkul C, et al. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002;36:439–50.PubMedCrossRef

14.

Sirica AE, Lai G-H, Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol. 2001;16:363–72.PubMedCrossRef

15.

Lai G-H, Radaeva S, Nakamura T, et al. Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated “intestinal-type” biliary cancer chemically induced in rat liver. Hepatology. 2003;31:1257–65.CrossRef

16.

Yokoyama S, Tsuji H, Lunz JG III, et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor b1 and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-specific biliary epithelial cells. Hepatology. 2000;32:26–35.CrossRef

17.

Yoon J-H, Higuchi H, Werneburg NW, et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002;122:985–93.PubMedCrossRef

18.

Werneburg NW, Yoon J-H, Higuchi H, et al. Bile acids activate EGF receptor via a TGF-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol. 2003;285:G31–6.PubMed

19.

Carraway KL, Ramsauer VP, Haq B, et al. Cell signaling through membrane mucins. Biol Essays. 2002;25:66–71.

20.

Ochiai A, Akimoto S, Kanai Y, et al. cerbB-2 Gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun. 1994;205:73–8.PubMedCrossRef

21.

Miyahara N, Shoda J, Ishige K, et al. MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. Eur J Cancer. 2008;44:1048–56.PubMedCrossRef

22.

Zhang Z, Lai G-H, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology. 2004;39:1028–37.PubMedCrossRef

23.

Lai G-H, Zhang Z, Sirica AE. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther. 2003;2:265–71.PubMed

24.

Wu T, Han C, Lunz JG III, Michalopoulos G, Shelhamer JH, Demetris AJ. Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology. 2002;36:363–73.PubMedCrossRef

25.

Eibl G, Bruemmer D, Okada Y, Duffy JP, Law RE, Reber HA, et al. PGE2 is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 2003;306:887–97.PubMedCrossRef

26.

Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003;63:2330–4.PubMed

27.

Scibetta AG, Albanese I, Morris J, et al. Regulation of MUC1 expression in human mammary cell lines by the c-ErbB2 and Ras signaling pathways. DNA Cell Biol. 2001;20:265–74.PubMedCrossRef

28.

Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1a (HIF-1a) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995–4004.PubMedCrossRef

29.

Yen L, Benlimame N, Nie Z-R, et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell. 2002;13:4029–44.PubMedCrossRef

30.

Goueli BS, Janknecht R. Upregulation of the catalytic telomerase subunit by the transcription factor ER 81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol. 2004;24:25–35.PubMedCrossRef

31.

Benckert C, Jonas S, Cramer T, et al. Transforming growth factor beta1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003;63:1083–92.PubMed

32.

Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001;61:6971–6.PubMed

33.

Kawamoto T. Development of molecular targeting therapy on gallbladder carcinoma using BK5.erbB2 transgenic mice. Tan Sui. 2010;31:395–408. (in Japanese).

34.

Kiguchi K, Ruffino L, Kawamoto T, et al. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res. 2005;11:5572–80.PubMedCrossRef

35.

Nonomura A, Ohta G, Nakanuma Y, et al. Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunohistochemical method. Liver. 1988;8:157–66.PubMed

36.

Nakazawa K, Dobashi Y, Suzuki S, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206:356–65.PubMedCrossRef

37.

Kawamoto T, Krishnamurthy S, Tarco E, et al. HER receptor family: novel candidate for target therapy for gallbladder and extrahepatic bile duct cancer. Gastrointest Cancer Res. 2007;1:221–7.PubMed

38.

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631.PubMedCrossRef

39.

Kawamoto T, Shoda J, Asano T, et al. Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer. 2002;98:427–34.PubMedCrossRef

40.

Asano T, Shoda J, Kawamoto T, et al. Expression of cyclooxygenase-2 in carcinoma of the gallbladder–crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res. 2002;8:1157–67.PubMed

41.

Shoda J, Ueda T, Kawamoto T, et al. Involvement of prostaglandin E2 and its specific receptor subtype EP4 in chronic proliferative cholangitis in the bile ducts of patients with hepatolithiasis. Clin Gastroenterol Hepatol. 2003;1:285–96.PubMedCrossRef

42.

Vadlamudi R, Mandal M, Adam L, et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene. 1999;18:305–14.PubMedCrossRef

43.

Benoit V, Relic B, de Leval X, et al. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene. 2004;23:1631–5.PubMedCrossRef

44.

Kiguchi K, Ruffino L, Kawamoto T, et al. Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice. Mol Cancer Ther. 2007;6:1709–17.PubMedCrossRef

45.

Mobius C, Demuth C, Aigner T, et al. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2007;33:1025–9.PubMedCrossRef

46.

Nakashima T, Kondoh S, Kitoh H, et al. Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis. Int J Mol Med. 2003;11:33–9.PubMed

47.

Hida Y, Moruta T, Fujita M, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinoma. Anticancer Res. 1999;19:2257–60.PubMed

48.

Liu Z, Sakamoto T, Ezure T, et al. Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. Hepatology. 1998;28:1260–8.PubMedCrossRef

49.

Polimeno L, Azzarone A, Zeng QH, et al. Cell proliferation and oncogene expression after bile duct ligation in the rat: evidence of a specific growth effect on bile duct cells. Hepatology. 1995;21:1070–8.PubMed

50.

Napoli J, Prentice D, Niinami C, et al. Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta in a bile duct ligated rat model of cirrhosis. Hepatology. 1997;26:624–633.

51.

Rashid A. Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am. 2002;11:995–1009.PubMedCrossRef

52.

Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998;29:175–80.PubMedCrossRef

53.

Shao J, Sheng H, Aramandla R, et al. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane induced rat colon tumors. Carcinogenesis. 1999;20:185–91.PubMedCrossRef

54.

Matsuzaki K, Date M, Furukawa F, et al. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res. 2000;60:1394–402.PubMed

55.

Shimizu T, Yokomuro S, Mizuguchi Y, et al. Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth. World J Gastroenterol. 2006;12:6316–24.PubMed

56.

Wu Q, Kiguchi K, Kawamoto T, et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. 2007;67:3794–800.PubMedCrossRef

57.

Ishige K, Shoda J, Kawamoto T, et al. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma. Int J Cancer. 2008;123:2915–22.PubMedCrossRef

58.

Kawakami K, Kawakami M, Husain S, et al. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res. 2002;62:3575–80.PubMed

59.

Shimamura T, Royal RE, Kioi M, et al. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res. 2007;67:9903–12.PubMedCrossRef

60.

LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127–37.PubMedCrossRef

61.

Mauro L, Surmacz E. IGF-I receptor, cell–cell adhesion, tumour development and progression. J Mol Histol. 2004;35:247–53.PubMedCrossRef

62.

Reinmuth N, Fan F, Liu W, et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest. 2002;82:1377–89.PubMed

63.

Imsumran A, Adachi Y, Yamamoto H, et al. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 2007;28:947–56.PubMedCrossRef

64.

Kornprat P, Rehak P, Rüschoff J, et al. Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours. J Clin Pathol. 2006;59:202–6.PubMedCrossRef

65.

Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24:3069–74.PubMedCrossRef

66.

Ramanthan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;doi:10.1007/s00280-009-0927-7.

67.

Gruenberger B, Schuller J, Wrba F, Tamandl D, Kaczirek K, Roka R, Friemann-Pircher S, Gruenberger T. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11:1142–8.PubMedCrossRef

68.

Safran H, Miner T, Resnick M, Dipetrillo T, McNulty B, Evans D, Joseph P, Plette A, Millis R, Sears D, Gutman N, Kennedy T. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. Am J Clin Oncol. 2008;31:140–4.PubMedCrossRef

69.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.PubMedCrossRef

70.

Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol. 2007;25:1539–44.PubMedCrossRef

71.

Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.PubMedCrossRef

72.

Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak E, Allen JN, Jain SR, Stuart K, Hatgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11:48–54.PubMedCrossRef

73.

Valle JW, Bridgewater JA, Roughton M, et al. ABC-03: a randomized, phase II/III study of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine for patients with advanced biliary tract cancers. J Clin Oncol. 2010;28 Suppl abstr:TPS218.

74.

Morizane C, Okusaka T. Current status and future prospects of development in molecular target therapy. Kan Tan Sui. 2009;58:361–8. (in Japanese).

Titel: Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options
verfasst von: Junichi Shoda
Kazunori Ishige
Hiroaki Sugiyama
Toru Kawamoto
Publikationsdatum: 01.07.2012
Verlag: Springer Japan
Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences / Ausgabe 4/2012
Print ISSN: 1868-6974
Elektronische ISSN: 1868-6982
DOI: https://doi.org/10.1007/s00534-012-0520-z

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Single-incision multiport laparoendoscopic surgery using a newly developed short-type flexible endoscope: a combined procedure of flexible endoscopic and laparoscopic surgery

Verification of Tokyo Guidelines for diagnosis and management of acute cholangitis

Is it possible to predict the development of an incisional surgical site infection and its severity after biliary tract surgery for benign disease?

Negative impact of low body mass index on surgical outcomes after hepatectomy for hepatocellular carcinoma

Role of chemotherapy in treatments for biliary tract cancer

Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors

Update Chirurgie